In Light of Alleged Deceptive Marketing Claims Made by Drug Makers, Parker Waichman LLP Addresses Issues Allegedly Related to the Safety and Effectiveness of Plavix

The Wall Street Journal reports that state authorities have been taking legal action against drug manufacturers over allegedly deceptive marketing claims; West Virginia and Mississippi are suing Bristol-Myers Squibb and Sanofi Aventis, alleging that the companies made false and misleading claims about Plavix. Parker Waichman LLP, who represents a number of Plavix patients in personal injury lawsuits, continues to offer legal advice to consumers who believe they were injured by the blood thinner.

New York, New York (PRWEB) April 23, 2013 -- Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, is addressing safety concerns and other issues related to Plavix in light of a Wall Street Journal* article published on April 22, 2013. The article reviews several drugs that are at the center of deceptive marketing lawsuits filed by state authorities; the drugs include Johnson & Johnson’s Risperdal, GlaxoSmithKline’s Avandia and Sanofi Aventis, and Bristol-Myers Squibb’s Plavix. The attorneys general of West Virginia and Mississippi have taken action against makers of Plavix, alleging, among other things, that they made false and misleading claims about the superiority of the blood thinner compared to Aspirin.

“For years, there has been mounting evidence suggesting that Plavix manufacturers put patients at risk by failing to properly warn about this drug,” said Daniel C. Burke, Senior Litigation Counsel at Parker Waichman LLP. “These legal actions help support those suspicions. Our firm continues to receive inquiries from Plavix users who allege that the medication caused injuries such as gastrointestinal and cerebral hemorrhaging.” The national personal injury firm has filed a number of lawsuits on behalf of Plavix patients. One case, for example, was filed on behalf of a Georgia man on Sept. 28, 2012, in the Supreme Court of the State of New York, County of New York (Index No. 156776/2012).

West Virginia and Mississippi allege that Plavix makers made deceptive marketing claims by stating that Plavix is superior to Aspirin, the Journal reports. Both states also allege that the companies should have known that Plavix may not be properly metabolized in a certain subgroup of patients.

Last month, Sanofi, in a filing** with the U.S. Securities and Exchange Commission noted that it was being investigated by the U.S. Department of Justice over disclosures it made about Plavix. The company stated in the filing that it learned about the probe in June 2012.

Research has suggested that use of Plavix may not be more effective than Aspirin. One study, published last August in the New England Journal of Medicine***, found that combination or “dual therapy” with Aspirin and Plavix does not significantly reduce the risk of a second stroke compared to Aspirin by itself. The study also found that adding Plavix to Aspirin therapy increased the risk of bleeding and death.

* http://online.wsj.com/article/SB10001424127887323361804578388873516625506.html
** http://www.sec.gov/Archives/edgar/data/1121404/000104746913002333/a2212980z20-f.htm
If you or a loved one experienced serious, life-threatening internal bleeding, heart attacks, strokes, or a blood disorder, and you believe Plavix is to blame, please contact their office by visiting the firm's Plavix side effects page at yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com
Contact Information
Gary Falkowitz
Parker Waichman LLP
http://www.yourlawyer.com
1-800-529-4636

Online Web 2.0 Version
You can read the online version of this press release here.